Cardiff Oncology (STU:XE7C) Total Liabilities: €12.51 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XE7C Cardiff Oncology Inc STU:XE7C
37 GF Score
Price €0.75
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Total Liabilities?

Cardiff Oncology STU:XE7C +1.22% 37 Total Liabilities is €12.51 Mil as of Mar. 2026. GuruFocus rates STU:XE7C with a GF Score™ of 37/100. The stock has 4 warning signs investors should review.

Cardiff Oncology's Total Liabilities for the quarter that ended in Mar. 2026 was €12.51 Mil.

Cardiff Oncology's quarterly Total Liabilities increased from Sep. 2025 (€12.77 Mil) to Dec. 2025 (€14.09 Mil) but then declined from Dec. 2025 (€14.09 Mil) to Mar. 2026 (€12.51 Mil).

Cardiff Oncology's annual Total Liabilities increased from Dec. 2023 (€10.91 Mil) to Dec. 2024 (€13.60 Mil) and increased from Dec. 2024 (€13.60 Mil) to Dec. 2025 (€14.09 Mil).

Cardiff Oncology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Total Liabilities Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.08 9.30 10.91 13.60 14.09

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.89 14.85 12.77 14.09 12.51
STU:XE7C
37GF Score
Cardiff Oncology Inc STU:XE7C
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cardiff Oncology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14+(0.087+0.0009999999999992
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.09

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=52.849-38.761
=14.09

Cardiff Oncology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.51+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=12.51

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=42.534-30.023
=12.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €12.51 Mil mean?
Cardiff Oncology (STU:XE7C) has a Total Liabilities of €12.51 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cardiff Oncology and its competitors.
Is Cardiff Oncology's Total Liabilities too high?
Cardiff Oncology's current Total Liabilities is €12.51 Mil. Overall, Cardiff Oncology has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Total Liabilities compare to MAIA and TELO?
Cardiff Oncology's Total Liabilities of €12.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cardiff Oncology and its competitors. Cardiff Oncology's current Total Liabilities is €12.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (STU:XE7C) has a current Total Liabilities of €12.51 Mil. The current Total Liabilities is €12.51 Mil. Cardiff Oncology's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cardiff Oncology (STU:XE7C), the current Total Liabilities is €12.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges CRDF:USA
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
37GF Score

Get the complete analysis for STU:XE7C

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price